Faron Pharmaceuticals: Updated BEXMAB phase I data - Redeye

Redeye leaves a comment following the recently announced updated data from the BEXMAB study with the company’s lead candidate bexmarilimab. We are encouraged to learn that the candidate continues to showcase impressive response rates.

Länk till analysen i sin helhet: https://www.redeye.se/research/991448/faron-pharmaceuticals-updated-bexmab-phase-i-data?utm_source=finwire&utm_medium=RSS